Target: GFAP
Conjugate: ATTO 390
Product Type: Monoclonal
Clone Number: N206A/8 (Formerly sold as S206A-8)
Immunogen: Synthetic peptide amino acids 411-422 (KTVEMRDGEVIK) of human GFAP; 100% identical in rat and mouse
Swiss-Prot: P14136
Purification: Protein G Purified
Storage Buffer: PBS pH 7.4, 50% glycerol, 0.1% sodium azide *Storage buffer may change when conjugated
Concentration: 1 mg/ml
Specificity: Detects ~50kDa. Cross-reacts with GFAP-R416W and other GFAP mutant proteins.
Cellular Localization: Cytoplasm
Scientific Background: The 50 kDa type III intermediate filament protein glial fibrillary acidic protein (GFAP) is a major structural component of astrocytes. GFAP associates with the calcium binding protein annexin II-p2 and S-100. Association with these proteins together with phosphorylation regulates GFAP polymerization. Astroycytes respond to brain injury by proliferatin (astrogliosis), and one of the first events to occur during astrocyte proiliferation is increased GFAP expression. Interestingly, antibodies to GFAP have been detected in individuals with dementia.
References: 1. Velasco M.E., et al. (1980) Cancer. 45:484.2. Bonnin J.M., et al. (1984) Acta Neuropathology. 62:185.3. Lee VM-Y., et al. (1984) J. Neurochem. 42:25-32 (1984).4. Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986).5. Schmidt ML et al; Lab Invest 56:282-294 (1987).6. Kosik KS et al; Neuron 1:817-825 (1988).7. Schmidt ML et al; Lab Invest 59:460-466 (1988).8. Mokuna, K, et al: J Neurosci Res 23:396 (1989).9. Molenaar, et al; Exp Neurology 108:1-9 (1990).10. Tohyama T et al; Am J Pathol, 142:871-882 (1993).11. Tohyama T et al; Am J Pathol 142:883-892 (1993).12. Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
